Please login to the form below

Not currently logged in
Email:
Password:

US court stands by Nycomed judgment

A US court has denied a motion brought by Sun Pharmaceutical and Teva to reverse a decision of patent infringement on Pfizer/Nycomed's Protonix

A US court has denied a motion brought by Teva Pharmaceutical of Israel and India's Sun Pharmaceutical to reverse an earlier decision of patent infringement on Pfizer/Nycomed's gastrointestinal drug Protonix (pantoprazole).

Teva says that it intends to continue to pursue all available legal routes, including appeals.

The district court in New Jersey will not overturn a ruling laid out in April on the validity of a patent on Protonix held by Pfizer's Wyeth unit. The court has not yet issued its underlying reasoning for the decision and both Teva and Sun said they continue to believe the patent is invalid and unenforceable.

The announcement saw Teva's shares fall to their lowest levels since March last year and Sun's stock also suffered. However both generic producers have not been prohibited from selling their copycat versions of Protonix before the expiry of Pfizer's marketing exclusivity in January 2011, as other claims concerning the validity of the patents, including patent misuse, are still pending.

Hakan Bjorklund, Nycomed chief executive, said: "We are very pleased that the court recognised and acknowledged that our patent is valid."

He added that patents "represent the foundation of pharmaceutical innovation".

The Swiss firm went on to say it "will continue to vigorously pursue its damage claims", noting that in 2007, before Teva and Sun started their at-risk launches of generic Protonix, sales of the drug reached $1.9bn, "and have since then decreased considerably".

Nycomed and Wyeth filed their patent infringement lawsuit against Teva and Sun in May 2004 and if the pantoprazole owners win all the cases, analysts have suggested that the latter two companies could indeed be hit hard financially. Observers believe that the damages could amount to $1-$2bn.

19th July 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics